Finance Watch: Biopharma VC Explosion Extends To Tools, Services
Codexis, Casdin Launch Accelerator; Resilience, SomaLogic Raise Mega-Rounds
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
You may also be interested in...
MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Further to the US Food and Drug Administration’s own plans to develop a framework to further the use of pharmacodynamic biomarkers and potentially streamline biosimilar development, the FDA has joined forces with US-based specialist SomaLogic, gaining access to its proprietary technology platform.